{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:01:55Z","timestamp":1767909715044,"version":"3.49.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2017.12.027","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T17:30:58Z","timestamp":1518024658000},"page":"S41-S52","source":"Crossref","is-referenced-by-count":28,"special_numbering":"S2","title":["ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)"],"prefix":"10.1016","volume":"24","author":[{"given":"J.","family":"Aguilar-Company","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garc\u00eda-Campelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Garrido-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ruiz-Camps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.12.027_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction)","volume":"24","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2017.12.027_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ceb.2008.12.012","article-title":"VEGFs and receptors involved in angiogenesis versus lymphangiogenesis","volume":"21","author":"Lohela","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.cmi.2017.12.027_bib4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/JTO.0b013e3181a97e31","article-title":"Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis","volume":"4","author":"Zhan","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib5","first-page":"2013","article-title":"Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer","volume":"56","author":"Yoshiji","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.cmi.2017.12.027_bib6","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1038\/sj.onc.1208246","article-title":"Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells","volume":"24","author":"Fan","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.cmi.2017.12.027_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0959-8049(98)00278-0","article-title":"Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma","volume":"35","author":"Tomisawa","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib8","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1158\/1078-0432.CCR-07-1888","article-title":"Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?","volume":"14","author":"Duncan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2017.12.027_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jnci\/89.12.881","article-title":"Angiogenesis as a prognostic indicator of survival in non\u2013small-cell lung carcinoma: a prospective study","volume":"89","author":"Fontanini","year":"1997","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cmi.2017.12.027_bib10","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.bjc.6600315","article-title":"Intra-tumoural microvessel density in human solid tumours","volume":"86","author":"Hasan","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cmi.2017.12.027_bib12","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib14","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib15","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib16","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib17","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib18","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin\u2013gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non\u2013small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib19","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non\u2013small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib20","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.12.027_bib21","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib22","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib23","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib25","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2017.12.027_bib26","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib27","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1097\/JTO.0b013e3181e59c24","article-title":"Anti\u2013vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells","volume":"5","author":"Novitskiy","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib28","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.4049\/jimmunol.1303116","article-title":"CD47 signaling regulates the immunosuppressive activity of VEGF in T cells","volume":"193","author":"Kaur","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.cmi.2017.12.027_bib29","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib30","doi-asserted-by":"crossref","first-page":"10715","DOI":"10.1007\/s13277-014-2369-z","article-title":"Risk of gastrointestinal perforation in cancer patients treated with aflibercept: a systematic review and meta-analysis","volume":"35","author":"Qi","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cmi.2017.12.027_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.21037\/jgo.2017.01.07","article-title":"Biological agents in gastrointestinal cancers: adverse effects and their management","volume":"8","author":"Arora","year":"2017","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/SAP.0b013e3181828141","article-title":"A\u00a0review on bevacizumab and surgical wound healing: an important warning to all surgeons","volume":"62","author":"Gordon","year":"2009","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.cmi.2017.12.027_bib33","doi-asserted-by":"crossref","first-page":"82473","DOI":"10.18632\/oncotarget.12666","article-title":"Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cmi.2017.12.027_bib34","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ejca.2011.03.005","article-title":"Haematologic toxicities associated with the addition of bevacizumab in cancer patients","volume":"47","author":"Schutz","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.critrevonc.2015.02.007","article-title":"Bevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trials","volume":"94","author":"Qi","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cmi.2017.12.027_bib36","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1200\/JCO.2007.13.9220","article-title":"Sepsis from liver abscesses in metastatic colorectal carcinoma after chemoimmunotherapy","volume":"26","author":"Lieuw-a-Fa","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib37","article-title":"Campylobacteremia in stage IV gliosarcoma with bevacizumab treatment","volume":"2","author":"Liu","year":"2012","journal-title":"J\u00a0Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.cmi.2017.12.027_bib38","first-page":"1423","article-title":"Pneumocystis pneumonia during adjuvant chemotherapy for advanced colon cancer\u2014a case report","volume":"42","author":"Fujiwara","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.cmi.2017.12.027_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.clbc.2011.10.003","article-title":"Pneumocystis jiroveci pneumonia in an atypical host","volume":"12","author":"Reinbolt","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1471-2334-14-198","article-title":"Necrotizing fasciitis caused by Haemophilus influenzae type b in a patient with rectal cancer treated with combined bevacizumab and chemotherapy: a case report","volume":"14","author":"Ugai","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.027_bib41","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/CAD.0b013e32833a5c51","article-title":"Indwelling central venous access port insertion during bevacizumab-based therapy","volume":"21","author":"Grenader","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.cmi.2017.12.027_bib42","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00520-014-2466-y","article-title":"Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis","volume":"23","author":"Berardi","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib43","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1200\/JCO.2012.42.6932","article-title":"Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non\u2013small-cell lung cancer: a randomized, controlled phase III trial","volume":"30","author":"Ramlau","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib44","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/bcp.12758","article-title":"Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis","volume":"81","author":"Zhang","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2017.12.027_bib45","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s10096-014-2160-5","article-title":"Actinomyces osteomyelitis in bisphosphonate-related osteonecrosis of the jaw (BRONJ): the missing link?","volume":"33","author":"De Ceulaer","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2017.12.027_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cmi.2017.12.027_bib47","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.21037\/jgo.2016.05.07","article-title":"Osteonecrosis of the jaw associated with ziv-aflibercept","volume":"7","author":"Mawardi","year":"2016","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib48","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.cmi.2017.12.027_bib49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5306\/wjco.v8.i3.203","article-title":"Evolving role of Sorafenib in the management of hepatocellular carcinoma","volume":"8","author":"Ziogas","year":"2017","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib50","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/13543784.15.5.553","article-title":"Sunitinib malate for the treatment of solid tumours: a review of current clinical data","volume":"15","author":"Motzer","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.cmi.2017.12.027_bib51","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s40265-015-0483-x","article-title":"Axitinib: a review in advanced renal cell carcinoma","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2017.12.027_bib52","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11523-017-0511-8","article-title":"Pazopanib: a review in advanced renal cell carcinoma","volume":"12","author":"Frampton","year":"2017","journal-title":"Target Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(16)00101-7","article-title":"Pazopanib for both GIST and soft-tissue sarcoma","volume":"17","author":"Nishida","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib54","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s40265-015-0406-x","article-title":"Regorafenib: a review of its use in patients with advanced gastrointestinal stromal tumours","volume":"75","author":"Shirley","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2017.12.027_bib55","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.2217\/fon-2017-0204","article-title":"Regorafenib as treatment for patients with advanced hepatocellular cancer","volume":"13","author":"Thillai","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib56","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14737140.2017.1344553","article-title":"Cabozantinib for the treatment of kidney cancer","volume":"17","author":"Abdelaziz","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cmi.2017.12.027_bib57","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/17425255.2014.885015","article-title":"Vandetanib for the treatment of thyroid cancer: an update","volume":"10","author":"Karras","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cmi.2017.12.027_bib58","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib60","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non\u2013small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.12.027_bib61","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1002\/ijc.28503","article-title":"Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor","volume":"134","author":"Santoni","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib62","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s13277-014-2722-2","article-title":"Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma","volume":"36","author":"Wang","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cmi.2017.12.027_bib63","doi-asserted-by":"crossref","first-page":"27252","DOI":"10.18632\/oncotarget.4583","article-title":"TLR3 agonist and sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression","volume":"6","author":"Ho","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cmi.2017.12.027_bib64","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2009.11.013","article-title":"Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell\u2013mediated immune response in mice","volume":"135","author":"Gu","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cmi.2017.12.027_bib65","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/leu.2008.58","article-title":"Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation","volume":"22","author":"Zhao","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2017.12.027_bib66","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000319498","article-title":"The effect of sunitinib on immune subsets in metastatic clear cell renal cancer","volume":"86","author":"Powles","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.cmi.2017.12.027_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020461","article-title":"Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma","volume":"18","author":"Randrup Hansen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cmi.2017.12.027_bib68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.critrevonc.2010.11.007","article-title":"Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials","volume":"80","author":"Schutz","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cmi.2017.12.027_bib69","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00280-016-3112-9","article-title":"Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network","volume":"78","author":"Shantakumar","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cmi.2017.12.027_bib70","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CMAR.S74202","article-title":"Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma","volume":"7","author":"Gunnarsson","year":"2015","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.cmi.2017.12.027_bib71","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2011.37.1195","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors","volume":"30","author":"Schutz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib72","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib73","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib74","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"Hutson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.12.027_bib76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1517\/14740338.2016.1122754","article-title":"The safety of regorafenib for the treatment of gastrointestinal stromal tumors","volume":"15","author":"Rutkowski","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2017.12.027_bib77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.12.027_bib78","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0140-6736(17)32365-6","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial","volume":"390","author":"Petrylak","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.12.027_bib79","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib81","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib82","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.12.027_bib83","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib84","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib85","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/annonc\/mdt523","article-title":"Final results from a randomized phase 3 study of FOLFIRI \u00b1 panitumumab for second-line treatment of metastatic colorectal cancer","volume":"25","author":"Peeters","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib87","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib88","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib89","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib90","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2004-09-3645","article-title":"HB-EGF\/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation","volume":"106","author":"Krampera","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2017.12.027_bib91","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/toxins5061180","article-title":"Heparin-binding epidermal growth factor-like growth factor\/diphtheria toxin receptor in normal and neoplastic hematopoiesis","volume":"5","author":"Vinante","year":"2013","journal-title":"Toxins"},{"key":"10.1016\/j.cmi.2017.12.027_bib92","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ijc.29045","article-title":"Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials","volume":"136","author":"Cui","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib93","first-page":"1028","article-title":"Modulation of phagocytosis by tumor promoters and epidermal growth factor in normal and transformed macrophages","volume":"40","author":"Laskin","year":"1980","journal-title":"Cancer Res"},{"key":"10.1016\/j.cmi.2017.12.027_bib94","doi-asserted-by":"crossref","first-page":"ra50","DOI":"10.1126\/scisignal.2002581","article-title":"Epidermal growth factor receptor is essential for Toll-like receptor 3 signaling","volume":"5","author":"Yamashita","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.cmi.2017.12.027_bib95","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.616","article-title":"Adverse effects associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib96","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cmi.2017.12.027_bib97","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/cup.12202","article-title":"Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors","volume":"40","author":"Brodell","year":"2013","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.cmi.2017.12.027_bib98","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib99","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.ctrv.2014.09.002","article-title":"Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis","volume":"40","author":"Funakoshi","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cmi.2017.12.027_bib100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12916-014-0203-5","article-title":"Incidence and risk of severe infections associated with anti\u2013epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis","volume":"12","author":"Qi","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib101","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/11598190-000000000-00000","article-title":"Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis","volume":"11","author":"Wang","year":"2011","journal-title":"Drugs R D"},{"key":"10.1016\/j.cmi.2017.12.027_bib102","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1684\/ejd.2012.1889","article-title":"Multiple abscesses in a patient treated with cetuximab","volume":"23","author":"Ricci","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.cmi.2017.12.027_bib103","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cmi.2017.12.027_bib104","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1684\/ejd.2010.1231","article-title":"Subcutaneous abscess as a side effect of cetuximab therapy","volume":"21","author":"Guerriero","year":"2011","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.cmi.2017.12.027_bib105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3816\/CLC.2008.n.010","article-title":"Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity","volume":"9","author":"Grenader","year":"2008","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib106","first-page":"338","article-title":"Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer","volume":"10","author":"Li","year":"2009","journal-title":"JOP"},{"key":"10.1016\/j.cmi.2017.12.027_bib107","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1634\/theoncologist.2011-0365","article-title":"Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review","volume":"17","author":"Bachet","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.cmi.2017.12.027_bib108","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/bjd.14756","article-title":"Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis","volume":"175","author":"Petrelli","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cmi.2017.12.027_bib109","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.cmi.2017.12.027_bib110","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1038\/sj.onc.1206779","article-title":"Biologic and therapeutic role of HER2 in cancer","volume":"22","author":"Menard","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.cmi.2017.12.027_bib111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.cmi.2017.12.027_bib112","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","article-title":"HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues","volume":"5","author":"Owens","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib113","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"Ruschoff","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cmi.2017.12.027_bib114","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2014mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib115","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib116","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"Nahta","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.cmi.2017.12.027_bib117","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib118","first-page":"5813","article-title":"Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer","volume":"62","author":"Kono","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.cmi.2017.12.027_bib119","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.bjc.6604963","article-title":"The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer","volume":"100","author":"Horlock","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib120","first-page":"317","article-title":"Immune effects of trastuzumab","volume":"2","author":"Nuti","year":"2011","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib121","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-014-3184-3","article-title":"Risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis","volume":"149","author":"Funakoshi","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.cmi.2017.12.027_bib122","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.breast.2017.08.001","article-title":"Liver toxicity of chemotherapy and targeted therapy for breast cancer patients with hepatitis virus infection","volume":"35","author":"Liu","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.cmi.2017.12.027_bib123","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib124","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cmi.2017.12.027_bib125","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u2018never smokers\u2019 and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cmi.2017.12.027_bib126","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Sordella","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.cmi.2017.12.027_bib127","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib128","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib129","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non\u2013small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib131","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation\u2013positive non\u2013small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib132","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation\u2013positive non\u2013small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib133","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib134","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non\u2013small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib135","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib136","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non\u2013small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.12.027_bib137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2005.23.16_suppl.1","article-title":"Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)","volume":"23","author":"Moore","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib138","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14737140.2017.1266265","article-title":"Advanced non\u2013small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs","volume":"17","author":"Bruckl","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cmi.2017.12.027_bib139","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2017.12.027_bib140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1345\/aph.1G387","article-title":"Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors","volume":"40","author":"Nelson","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2017.12.027_bib141","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.clbc.2016.05.016","article-title":"Neratinib, a novel HER2-targeted tyrosine kinase inhibitor","volume":"16","author":"Tiwari","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib142","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1080\/14740338.2016.1236910","article-title":"The safety of afatinib for the treatment of non\u2013small cell lung cancer","volume":"15","author":"Barron","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2017.12.027_bib143","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2174\/1389200218666170105165832","article-title":"Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacotherapy: management with clinical pharmacology","volume":"18","author":"Fujita","year":"2017","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.cmi.2017.12.027_bib144","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1586\/14737140.2016.1162103","article-title":"The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non\u2013small-cell lung cancer","volume":"16","author":"Gao","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cmi.2017.12.027_bib145","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1183\/09031936.00172007","article-title":"Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases","volume":"32","author":"Burgel","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2017.12.027_bib146","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.lungcan.2011.04.008","article-title":"Gefitinib vs. chemotherapy as first-line therapy in advanced non\u2013small cell lung cancer: meta-analysis of phase III trials","volume":"74","author":"Ku","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cmi.2017.12.027_bib147","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","article-title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation\u2013positive non\u2013small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib148","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non\u2013small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2017.12.027_bib149","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18300326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18300326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T01:31:53Z","timestamp":1719797513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18300326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":149,"alternative-id":["S1198743X18300326"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.12.027","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}